Literature DB >> 20465606

Glucagonoma syndrome and necrolytic migratory erythema.

Inês Lobo1, André Carvalho, Cláudia Amaral, Susana Machado, Rui Carvalho.   

Abstract

The glucagonoma syndrome is a rare disorder, characterized by necrolytic migratory erythema, elevated serum glucagon levels, abnormal glucose tolerance, weight loss, and anemia in association with a glucagon-secreting alpha-cell tumor of the pancreas. We present a 67-year-old diabetic patient with extensive cutaneous lesions, weight loss, and poor glycemic control. The clinical investigation revealed a pancreatic glucagonoma with resolution of the cutaneous and systemic features after surgical removal. The dermatologic and endocrine approach to this syndrome is discussed here. Early recognition and treatment may prevent metastatic disease and ensure its cure with resolution of the cutaneous and catabolic manifestations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465606     DOI: 10.1111/j.1365-4632.2009.04220.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  7 in total

1.  [Migratory necrolytic erythema as a manifestation of pancreatic neuroendocrine tumor. Clinical-radiological evaluation].

Authors:  Gonzalo Dulcich; Marcos Alejandro Mestas Nuñez; Ernestina Maria Jose Gentile
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2022-06-06

2.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

3.  Glucagonoma syndrome: a case report.

Authors:  Pablo Granero Castro; Alberto Miyar de León; Jose Granero Trancón; Paloma Alvarez Martínez; Jose A Alvarez Pérez; Jose C Fernández Fernández; Carmen M García Bernardo; Luis Barneo Serra; Juan J González González
Journal:  J Med Case Rep       Date:  2011-08-22

4.  Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor.

Authors:  Sheng-li Wu; Ji-gang Bai; Jun Xu; Qing-yong Ma; Zheng Wu
Journal:  World J Surg Oncol       Date:  2014-07-17       Impact factor: 2.754

5.  Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.

Authors:  Hameem I Kawsar; Alma Habib; Azhar Saeed; Anwaar Saeed
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-11-01

6.  Diarrhea: a missed D in the 4D glucagonoma syndrome.

Authors:  Marlone Cunha-Silva; Julia Guimarães da Costa; Guilherme Amorim Souza Faria; Juliana Yumi Massuda; Maria Letícia Cintra; Larissa Bastos Eloy da Costa; Vítor Marques Assad; Elaine Cristina de Ataíde; Daniel Ferraz de Campos Mazo; Tiago Sevá-Pereira
Journal:  Autops Case Rep       Date:  2019-11-27

7.  How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

Authors:  Carmen Sorina Martin; Ovidiu Dumitru Parfeni; Liliana Gabriela Popa; Mara Madalina Mihai; Dana Terzea; Vlad Herlea; Mirela Gherghe; Razvan Adam; Osama Alnuaimi; Valentin Calu; Adrian Miron; Silvius Negoita; Cornelia Nitipir; Simona Fica
Journal:  Diagnostics (Basel)       Date:  2022-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.